Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C32H27Cl2N3O4 |
| Molecular Weight | 588.48 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2C=C(C=CC2=C1)C3=CC(=NN3[C@@H](C)C4=CC=C(C=C4)C(=O)NCCC(O)=O)C5=CC(Cl)=CC(Cl)=C5
InChI
InChIKey=DNTVJEMGHBIUMW-IBGZPJMESA-N
InChI=1S/C32H27Cl2N3O4/c1-19(20-3-5-21(6-4-20)32(40)35-12-11-31(38)39)37-30(18-29(36-37)25-14-26(33)17-27(34)15-25)24-8-7-23-16-28(41-2)10-9-22(23)13-24/h3-10,13-19H,11-12H2,1-2H3,(H,35,40)(H,38,39)/t19-/m0/s1
| Molecular Formula | C32H27Cl2N3O4 |
| Molecular Weight | 588.48 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:10:00 UTC 2023
by
admin
on
Fri Dec 15 16:10:00 UTC 2023
|
| Record UNII |
CCP2U6LWTP
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB194081
Created by
admin on Fri Dec 15 16:10:00 UTC 2023 , Edited by admin on Fri Dec 15 16:10:00 UTC 2023
|
PRIMARY | |||
|
DB12044
Created by
admin on Fri Dec 15 16:10:00 UTC 2023 , Edited by admin on Fri Dec 15 16:10:00 UTC 2023
|
PRIMARY | |||
|
CCP2U6LWTP
Created by
admin on Fri Dec 15 16:10:00 UTC 2023 , Edited by admin on Fri Dec 15 16:10:00 UTC 2023
|
PRIMARY | |||
|
CHEMBL1933349
Created by
admin on Fri Dec 15 16:10:00 UTC 2023 , Edited by admin on Fri Dec 15 16:10:00 UTC 2023
|
PRIMARY | |||
|
11570626
Created by
admin on Fri Dec 15 16:10:00 UTC 2023 , Edited by admin on Fri Dec 15 16:10:00 UTC 2023
|
PRIMARY | |||
|
100000178371
Created by
admin on Fri Dec 15 16:10:00 UTC 2023 , Edited by admin on Fri Dec 15 16:10:00 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
The addition of MK-0893 to either metformin or sitagliptin compared favorably with the classical metformin–sitagliptin combination. However, plasma levels of LDL cholesterol and liver transaminases were increased in some studies with MK-0893.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
